Daniel Zakowiecki, Peter Edinger, Markos Papaioannou, Michael Wagner, Tobias Hess, Jadwiga Paszkowska, . . . Dorota Haznar Garbacz. (2024). Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. MDPI AG.
Chicago Style (17th ed.) CitationDaniel Zakowiecki, et al. Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. MDPI AG, 2024.
MLA (9th ed.) CitationDaniel Zakowiecki, et al. Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. MDPI AG, 2024.
Warning: These citations may not always be 100% accurate.